Endocrine & Hormonal Peptides

Endocrine peptides are among the most clinically important peptide therapeutics, with insulin analogs alone representing a multi-billion dollar pharmaceutical market. These peptides regulate critical metabolic and hormonal processes including glucose homeostasis, calcium metabolism, growth hormone secretion, and bone remodeling.

The insulin analogs in this category (aspart, glargine, degludec) represent successive generations of engineered modifications to the human insulin molecule, each designed to optimize pharmacokinetic profiles for different clinical needs: rapid-acting (aspart), long-acting peakless (glargine), and ultra-long-acting (degludec). Calcitonin and teriparatide both target bone metabolism but through opposing mechanisms: calcitonin inhibits osteoclast-mediated bone resorption, while teriparatide (PTH 1-34) stimulates osteoblastic bone formation when administered intermittently. Glucagon serves as the primary counter-regulatory hormone to insulin, with FDA-approved formulations for hypoglycemia rescue. Somatostatin, the "universal inhibitor," suppresses the secretion of growth hormone, insulin, glucagon, and numerous gastrointestinal hormones.

All peptides in this category have strong clinical evidence from extensive randomized controlled trials and regulatory approval for at least one indication.